Drug Repurposing: Hydroxyurea Therapy Improves the Transfusion-Free Interval in HbE/Beta-Thalassemia—Major Patients with the Xmn I Polymorphism
- 17 August 2021
- journal article
- research article
- Published by SAGE Publications in Genetic Testing and Molecular Biomarkers
- Vol. 25 (8) , 563-570
Abstract
Aims: HbE/β-thalassemia is the most prevalent form of severe β-thalassemia in Asian countries. Hydroxyurea (HU) is the most common drug used for the management of sickle-cell anemia but not thalassemia. In this study, we aimed to assess clinical HU response among the Bengali HbE/β-thalassemia patients with respect to the Xmn I γ G globin polymorphism and elucidate the association between this polymorphism and HU response efficacy. Materials and Methods: We enrolled 49 transfusion-dependent patients with HbE/β-thalassemia. Fetal hemoglobin levels were measured using high-performance liquid chromatography and complete blood counts were determined pre- and post-HU therapy. Polymerase chain reaction-restriction fragment length polymorphism analyses were performed for genotyping the Xmn I γ G globin polymorphism. Results: A total of 30 (61.22%) patients were found to be responders, whereas the remaining 19 (38.78%) were nonresponders. We found 33 patients with the heterozygous (C/T) and three with the homozygous mutant (T/T) genotype status. We obtained a statistically significant correlation ( p < 0.001) between the Xmn I polymorphism genotype and transfusion-free interval. Patients with the Xmn I polymorphism were found to be good responders for HU therapy and showed increased hemoglobin levels. Conclusions: Our findings indicate that HU is a potential drug candidate for thalassemia management, particularly for HbE/β-thalassemia. These results hold implications in repurposing HU as an effective and efficient therapy for HbE/β-thalassemia.Keywords
All Related Versions
This publication has 26 references indexed in Scilit:
- Modifying effect of XmnI, BCL11A, and HBS1L-MYB on clinical appearancesHematology/Oncology and Stem Cell Therapy, 2016
- Hydroxyurea Treatment in Transfusion-Dependent β-Thalassemia PatientsIranian Red Crescent Medical Journal, 2014
- Genetic association studies in β-hemoglobinopathiesHematology-American Society Hematology Education Program, 2013
- Influence of Xmn 1Gγ (HBG2 c.-211 C → T) Globin Gene Polymorphism on Phenotype of Thalassemia Patients of North IndiaIndian Journal of Hematology and Blood Transfusion, 2013
- Prevalence of β-thalassemia and other haemoglobinopathies in six cities in India: a multicentre studyJournal of Community Genetics, 2012
- Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-β-thalassaemia: a genotypic and phenotypic studyJournal of Clinical Pathology, 2010
- Studies in haemoglobin E beta‐thalassaemiaBritish Journal of Haematology, 2008
- Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermediaTransfusion, 2007
- In vivo and in vitro studies of fetal hemoglobin induction by hydroxyurea in β-thalassemia/hemoglobin E patientsExperimental Hematology, 2005
- Do alpha deletions influence hydroxyurea response in thalassemia intermedia?Hematology, 2005